ARTICLE | Product Development
Panacos Chronicles
January 26, 2009 8:00 AM UTC
Panacos(NASDAQ:PANC) fell 62% to $0.07 per share last week, giving it a $3.7 million market cap, after selling its HIV compound bevirimat to Myriad Genetics(NASDAQ:MYGN). After Panacos went public via a merger with V. I. Technologies, the company reached a peak valuation of about $500 million in September 2005. Selected events tracked against Panacos' weekly stock price since March 2005.
A. 3/11/05 - Public company V. I. Technologies merges with privately held Panacos...